Last reviewed · How we verify
Platinum-Based Drug
Platinum-Based Drug is a Platinum-based chemotherapy agent Small molecule drug developed by Chinese Academy of Medical Sciences. It is currently in Phase 3 development for Various solid tumors (specific indication in phase 3 trial not specified). Also known as: Cisplatin.
Platinum-based drugs form covalent crosslinks with DNA, preventing replication and transcription to induce cancer cell death.
Platinum-based drugs form covalent crosslinks with DNA, preventing replication and transcription to induce cancer cell death. Used for Various solid tumors (specific indication in phase 3 trial not specified).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Platinum-Based Drug |
|---|---|
| Also known as | Cisplatin |
| Sponsor | Chinese Academy of Medical Sciences |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Platinum compounds bind to DNA and form interstrand and intrastrand crosslinks, which distort the DNA helix and block DNA synthesis and repair mechanisms. This leads to apoptosis in rapidly dividing cancer cells. The mechanism is non-selective and affects both tumor and normal cells, particularly those with high proliferation rates.
Approved indications
- Various solid tumors (specific indication in phase 3 trial not specified)
Common side effects
- Nephrotoxicity
- Ototoxicity
- Myelosuppression
- Nausea and vomiting
- Peripheral neuropathy
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
- JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer (PHASE2)
- Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (PHASE3)
- Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma (PHASE1, PHASE2)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Platinum-Based Drug CI brief — competitive landscape report
- Platinum-Based Drug updates RSS · CI watch RSS
- Chinese Academy of Medical Sciences portfolio CI
Frequently asked questions about Platinum-Based Drug
What is Platinum-Based Drug?
How does Platinum-Based Drug work?
What is Platinum-Based Drug used for?
Who makes Platinum-Based Drug?
Is Platinum-Based Drug also known as anything else?
What drug class is Platinum-Based Drug in?
What development phase is Platinum-Based Drug in?
What are the side effects of Platinum-Based Drug?
What does Platinum-Based Drug target?
Related
- Drug class: All Platinum-based chemotherapy agent drugs
- Target: All drugs targeting DNA
- Manufacturer: Chinese Academy of Medical Sciences — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Various solid tumors (specific indication in phase 3 trial not specified)
- Also known as: Cisplatin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing